The importance of correct assignment of CYP2B6 genetic variants with respect to cyclophosphamide metabolizer status

American Journal of Hematology

Volumn 86, Issue 4, 2011, Pages 383-384

  Helsby, Nuala ^a   Tingle, Malcolm ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19;

ALLELE; DISEASE COURSE; DRUG METABOLISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; LETTER; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ARYL HYDROCARBON HYDROXYLASES; CYCLOPHOSPHAMIDE; GENOTYPE; HUMANS; METABOLIC CLEARANCE RATE; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 79953066957     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21987     Document Type: Letter

References (14)

1. Melanson SE, Stevenson K, Kim H, et al. Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation. Am J Hematol 2010; 85: 967-971.
2. Xie H, Griskevicius L, Stahle L, et al. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur J Pharm Sci 2006; 27: 54-61.
3. Nakajima M, Komagata S, Fujiki Y, et al. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics 2007; 17: 431-444.
4. Timm R, Kaiser R, Lotsch J, et al. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics J 2005; 5: 365-373.
5. Ekhart C, Doodeman VD, Rodenhuis S, et al. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1, and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics 2008; 18: 515-523.
6. Helsby NA, Hui C-Y, Goldthorpe MA, et al. The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. Br J Clin Pharmacol 2010; 70: 844-853.
7. Zanger UM, Klein K, Saussele T, et al. Polymorphic CYP2B6: Molecular mechanisms and emerging clinical significance. Pharmacogenomics 2007; 8: 743-759.
8. Hesse LM, He P, Krishnaswamy S, et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 2004; 14: 225-238.
9. Tran A, Bournerias F, Le Beller C, et al. Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1, and GSTP1 polymorphisms. Br J Clin Pharmacol 2008; 65: 279-280.
10. de Jonge ME, Huitema AD, Beijnen JH, et al. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer 2006; 4: 1226-1230.
11. McCune JS, Batchelder A, Deeg HJ, et al. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: Pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant 2007; 13: 853-862.
12. Rocha V, Porcher R, Fernandes JF, et al. Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia 2009; 23: 545-556.
13. Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11: 399-415.
14. Takada K, Arefayene M, Desta Z, et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 2004; 50: 2202-2210.